Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) announced its quarterly earnings results on Thursday. The company reported $0.18 earnings per share for the quarter, Zacks reports. Chugai Pharmaceutical had a net margin of 33.85% and a return on equity of 22.30%.

Chugai Pharmaceutical Price Performance

OTCMKTS:CHGCY opened at $21.61 on Friday. The company’s 50-day moving average is $21.65 and its two-hundred day moving average is $22.43. Chugai Pharmaceutical has a 1-year low of $14.52 and a 1-year high of $26.00. The firm has a market capitalization of $71.12 billion, a price-to-earnings ratio of 26.06 and a beta of 0.81.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.